Medizone Announces Canadian Blood Forces Program Status
New York City – October 3, 1995 – Medizone International,
Inc. (OTC BB MZEI.U) reported on the status of the third
stage of the research on its blood decontamination process
being investigated by the Department of Defense, Candadian
Blood Forces Program in a letter to the Company dated
September 29, 1995. Commodore Michael E. Shannon M.D.
(Navy), Deputy Surgeon General, Canada, stated:
“As you are aware, the Department of National Defense (DND)
has been conducting a series of studies to evaluate the
efficacy of ozone in blood sterilization. Specifically, a
combination of ozone and leukocyte filtration could
inactivate/remove infectious viruses from blood. The initial
phases of this work have been conducted at the Animal Disease
Research Institute of Agriculture and Agri-Food Canada under
the direction of Dr. F. Quimby, who was at the time on
sabbatical from Cornell University.
As a surrogate for the human immunodeficiency virus, a simian
immunodeficiency virus (SIV) was selected for the
investigation and cynomologus macaques were used for the in
Ozonation was delivered by either of two commercially
available instruments; one of which as you know, was obtained
from Medizone and utilized hollow fibre technology.
During the course of the study, it was determined that the
SIV isolate characterized and selected for the study was
capable of inducing an AIDS-like clinical picture with
virtually 100 percent mortality. It was decided to
concentrate the effort at this point on the ozonation of
plasma as an initial step before proceeding to the red blood
cells and whole blood. Blood was drawn from the macaques,
plasma was extracted and SIV introduced. This spiked plasma
was then ozonated and injected back into the macaques. No
clinical signs were observed after 35 days and subsequent
assessment by PCR and pathological examination was unable to
detect the existence of any virus in these animals. In the
virus controlled experiment, the monkeys developed clinical
signs by day seven and experienced 100 percent mortality.
The final stage of the process is now underway involving red
cells in which red cells function and morphology will be
examined after ozonation. Not withstanding the limitations
of current technology, we anticipate the completion of this
work by Christmas.
Should this project prove successful, recognizing that it is
a generic proof of concept study only, you can appreciate
that the potential impact on blood transfusion technology in
North America will be profound.”
Medizone is highly encouraged by Commodore Shannon’s letter.
But the Company also recognizes that additional research will
be required before its patented process will be available for
application for licensing approval of its blood
Medizone is developing MEDIZONE (c), an ozone-based treatment
for diseases caused by lipid enveloped viruses, including
Acquired Immunodeficiency Syndrome (AIDS), Hepatitis B, and
Herpes; and is also developing its patented technology for
the decontamination of blood and blood products.
Medizone International, Inc has a Front Page Web site at the
following internet address: